2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Aquaporin
  5. Aquaporin Inhibitor

Aquaporin Inhibitor

Aquaporin Inhibitors (16):

Cat. No. Product Name Effect Purity
  • HY-161834
    RG100204
    		Inhibitor 99.50%
    RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H2O2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice.
  • HY-N6016
    Bacopaside II
    		Inhibitor 98.86%
    Bacopaside II, an extract from the medicinal herb Bacopa monnieri. Bacopaside II is the inhibitor for AQP1 that exhibits anti-angiogenesis activity. Bacopaside II exhibits cytotoxicity and induces apoptosis in cancer cells.
  • HY-W017091
    3-Phenoxy-1,2-propanediol
    		Inhibitor
    3-Phenoxy-1,2-propanediol (compound 15) is a weak aquaporin 4 (AQP4) inhibitor. 3-Phenoxy-1,2-propanediol is an important intermediate for pharmaceuticals.
  • HY-148823
    RF03176
    		Inhibitor
    RF03176 is an aquaporin-9 (AQP-9) inhibitor, also exhibiting moderate inhibition effects on mAQP3 and mAQP7. RF03176 shows no activity against mAQP8.
  • HY-P991869
    Aquaporumab
    		Inhibitor
    Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
  • HY-110200
    TC AQP1 1
    		Inhibitor 98.03%
    TC AQP1 1 (m-Phenylenediacrylic acid) is a potent AQP1 inhibitor. TC AQP1 1 inhibits AQP1-mediated water flux in oocytes, with an IC50 of 8 μM.
  • HY-N2057
    Steviol
    		Inhibitor 99.85%
    Steviol is the main metabolite of steviol glycosides and an inhibitor of AQP2/CFTR. Steviol slows down the growth of renal cysts by inhibiting the activity of CFTR, reducing the expression of AQP2, and promoting the degradation of AQP2 and CFTR. Steviol can be used in the research of polycystic kidney disease.
  • HY-N2013
    Aristolactam I
    		Inhibitor 99.44%
    Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis.
  • HY-N4246
    Bacopaside I
    		Inhibitor 99.20%
    Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.
  • HY-157226
    ORI-TRN-002
    		Inhibitor
    ORI-TRN-002 is an AQP4 inhibitor with an IC50 value of 3μM. ORI-TRN-002 can be used in the research area of cerebral edema.
  • HY-N4246R
    Bacopaside I (Standard)
    		Inhibitor
    Bacopaside I (Standard) is the analytical standard of Bacopaside I. This product is intended for research and analytical applications. Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.
  • HY-N6016R
    Bacopaside II (Standard)
    		Inhibitor
    Bacopaside II (Standard) is the analytical standard of Bacopaside II. This product is intended for research and analytical applications. Bacopaside II, an extract from the medicinal herb Bacopa monnieri, blocks the Aquaporin-1 (AQP1) water channel and impairs migration of cells that express AQP1. Bacopaside II induces cell cycle arrest and apoptosis.
  • HY-148600
    HTS13286
    		Inhibitor
    HTS13286 is a novel AQP9 inhibitor. HTS13286 prevents the LPS-induced increase of NO. HTS13286 reduces glucose output. HTS13286 can be used in the research of endotoxin shock.
  • HY-157979
    AQP3-IN-1
    		Inhibitor
    AQP3-IN-1 (compounds 3) is an AQP3 inhibitor with a IC50 value of 8.91 μM. AQP3-IN-1 inhibits cell proliferation of melanoma cells.
  • HY-18805
    Nicotinanilide
    		Inhibitor 99.84%
    Nicotinanilide (N-Phenylnicotinamide) (Compound 12) is an aquaporin 4 (AQP4) inhibitor. Nicotinanilide can be used for research on diseases associated with AQP4 dysfunction, such as epilepsy and migraine.
  • HY-N2057R
    Steviol (Standard)
    		Inhibitor
    Steviol (Standard) is the analytical standard of Steviol (HY-N2057). This product is intended for research and analytical applications. Steviol is the main metabolite of steviol glycosides and an inhibitor of AQP2/CFTR. Steviol slows down the growth of renal cysts by inhibiting the activity of CFTR, reducing the expression of AQP2, and promoting the degradation of AQP2 and CFTR. Steviol can be used in the research of polycystic kidney disease.